The event will run from 12pm until 5pm at Inaphaea’s labs at MediCity Nottingham and will give guests the opportunity to see the new equipment including the recently acquired scientific assets from Imagen.
The day will begin with lunch followed by introductions from Stella James, Executive Director of Business Development at BioNow, and Andrew Carnegie, Head of Strategic Commercial Development at Inaphaea. Next, a range of growing life science company leaders will take to the stage to showcase their companies.
Keynote speakers
Company showcases
Dr Peter De’Ath, Head of Client Management at HistologiX, will kick off the company showcases. HistologiX is the leading independent GLP accredited, specialised histology and immunohistochemistry company in the UK that provides regulatory, clinical, and veterinary services to the pharma and biotech industries. In his role, Peter is a key point of contact for clients, providing regular project updates and ensuring smooth project delivery across histology, immunohistochemistry, and digital image analysis.
Managing Director of Inspiralis, Natassja Bush will also speak at the event. Inspiralis Limited is a small biotech that supports drug discovery by producing and supplying DNA modifying enzymes and their substrates to those looking for novel antimicrobials and anti-cancer drugs. The company also offers contract research services in the form of drug screening and mode of action studies. Having worked at Inspiralis as a scientist ten years earlier, Nastassja was approached to take on the role of joint Managing Director.
Founder and CSO of Venomtech Ltd, Steven Trim will also take to the stage to discuss his work. Having started his drug discovery career as a molecular biologist, biochemist and safety delegate at Pfizer, where he worked for ten years, Steve started Venomtech in 2010. Venomtech is the UK’s only commercial venom laboratory and helps customers worldwide to make advances in drug discovery, crop protection, and cosmetics.
Also showcasing their business is Professor Claire Thompson, Founder and CEO of Agility Life Sciences. Claire is a multi-award-winning scientist, entrepreneur, NED and philanthropist with more than 20 years of experience in the pharmaceutical industry. She founded Agility Life Sciences to ensure clients’ molecules have the best chance of success in preclinical studies and enable them to be accelerated to clinic or commercialisation. Inaphaea BioLabs recently entered into a collaborative agreement with Agility Life Sciences to provide a single point of contact for customers to formulate and test their drug candidates. Find out more here.
Insights from Inaphaea
The event will then feature talks from Inaphaea Scientific Advisor Dr Gareth Griffiths and CSO of ValiRx and Inaphaea and Executive Director of Milner Therapeutics Institute, Dr Cathy Tralau-Stewart.
Gareth co-founded Imagen Therapeutics and joined the Inaphaea team following the acquisition of Imagen’s scientific assets. He will outline his plans to continue his work building complex, well-defined models, including 2D and 3D tumour spheroid models as well as more advanced co-culture models, that will be fully characterised for use in client projects.
Cathy is an experienced therapeutics development scientist and pharmacologist who has worked within some of the world’s leading pharma and academic research establishments. At the event, she will discuss her work to improve target validation in early drug discovery.
Dr Suzy Dilly, Director of Inaphaea, will conclude the event with closing remarks.
The event is free to attend. For more information or to register, click here.
